Breast Care A-Z · Concept · FAMILYHX

Family history (breast cancer)

also: family history of breast cancer, hereditary breast cancer risk, inherited breast cancer risk

A significant family history of breast cancer is a pattern of close relatives affected — particularly at a young age or on the same side of the family — that can raise your own risk above average. You may be wondering whether your history counts, or have already been told it does; the key question is what makes it significant.

Quick answers

My mother had breast cancer in her 60s — am I at higher risk?

A single first-degree relative diagnosed in their 60s gives a modest increase in risk over the general population, but usually not enough to change routine surveillance. The standard NHS screening programme is appropriate for this pattern. Risk increases more meaningfully with multiple affected relatives, younger ages at diagnosis, or other features.

What if I'm adopted and don't know my biological family history?

Adopted patients can still be assessed for risk based on personal factors (breast density, hormonal history, biopsy history). Genetic testing is sometimes offered without family history — particularly if the patient has had an early-onset cancer or specific concerning features. The family-history clinic can advise.

Does it matter which side of the family the cancer is on?

Yes — both sides count, but they are assessed separately. A father with three sisters with breast cancer is a strong family-history signal even though the patient's mother's side may be unaffected. Risk-assessment tools take both maternal and paternal patterns into account.

BREASTORY ENCYCLOPEDIA · PLATE XXXIX GENETICS · RISK ASSESSMENT family history of breast cancer hereditary risk stratification · NICE NG151 structured assessment of genetic risk to guide surveillance, testing, and prevention FIG 01 family pedigree · risk stratification · referral thresholds Gen I Gen II Gen III Legend Female unaffected Female affected Male unaffected Proband Deceased i proband ii 1st-degree relative iii 2nd-degree relative iv affected (bilateral BC) v early onset (<40 yrs) RISK STRATIFICATION (NICE) Low: 1 FDR diagnosed >40 yrs Moderate: 1 FDR <40 yrs or 2 FDRs >50 yrs High: 3+ relatives any age, or 2 <50 yrs or BRCA1/2 criteria met FDR = first-degree relative REFERRAL THRESHOLDS Low risk → GP reassurance Moderate → Genetics/breast clinic High → Specialist genetics centre Referral criteria per NICE NG151 2023; consider Manchester score if BRCA suspected FIG 01 — Family pedigree · 3-generation pedigree showing affected relatives and proband identification FIG 02 lower/moderate vs high/very high risk Lower / Moderate Risk High / Very High Risk Feature # affected relatives 1–2 relatives 3 or more relatives Age at diagnosis >50 years <40 years Relationship 2nd degree relative 1st degree relative Bilaterality No bilateral cancer Bilateral cancer present Male breast cancer None Male relative affected Ovarian cancer None Ovarian + breast cancer Ashkenazi Jewish No Increased prevalence BRCA testing Not indicated Indicated MRI Not required Annual breast MRI Chemoprevention Not offered Tamoxifen/anastrozole FIG 03 lifetime risk by category Category Lifetime Risk Management General population ~12% Screening age 50–70 1 FDR (>50 at dx) ~16–19% Mammogram from age 40 1 FDR (<40 at dx) ~20–30% Annual mammogram 30–40 2 FDRs ~25–35% Annual mammogram + USS Moderate risk (NICE) 17–30% 5-yearly mamm from 40 High risk (NICE) >30% Annual mamm from 30–40 BRCA1 carrier ~72% Annual MRI from age 30 BRCA2 carrier ~69% Annual MRI from age 30 TP53 (Li-Fraumeni) Near 100% Annual MRI from age 20 FIG 04 risk pathway Risk Pathway 1 FH concern 2 GP assessment 3 NICE risk criteria 4 Genetics referral 5 Stratified surveillance 6 Prevention counselling FIG 05 risk group tiles Low Risk ~12–16% lifetime; GP reassurance only Moderate Risk 17–30% lifetime; breast clinic referral High Risk >30% lifetime; genetics referral BRCA1 Carrier ~72% lifetime; annual MRI from 30 BRCA2 Carrier ~69% lifetime; annual MRI from 30 TP53 / Li-Fraumeni Near 100% lifetime; MRI from age 20 FIG 06 key statistics ~15% of breast cancers are hereditary [1] 2× risk with one first-degree relative [2] ~6% of women are high-risk (NICE) [3] 1 in 8 lifetime risk general population [4] FIG 07 references References 1. NICE NG151. Familial breast cancer: classification, care and managing breast cancer 2023. 2. Collaborative Group on Hormonal Factors. Lancet 2001;358:1389. 3. Antoniou A et al. BMJ 2010;341:c3832. 4. Cancer Research UK. Breast cancer statistics 2024. 5. Evans DG et al. Familial breast cancer. Lancet Oncol 2021. Clinically authored by Dr Fiona Tsang-Wright , FRCS (Gen Surg) GMC 4549831 · ORCID 0000-0003-4801-026X
Visual Reference · Family history (breast cancer)
Open full size ↗
Definition
A family history of breast cancer is a pattern of breast or ovarian cancer in close relatives that raises a person's own lifetime risk above the general population baseline — and triggers structured assessment, surveillance, and (where appropriate) genetic testing or risk-reducing options.

Common questions The questions patients ask first

My mother had breast cancer in her 60s — am I at higher risk?
A single first-degree relative diagnosed in their 60s gives a modest increase in risk1 over the general population, but usually not enough to change routine surveillance. The standard NHS screening programme is appropriate for this pattern. Risk increases more meaningfully with multiple affected relatives, younger ages at diagnosis, or other features.
What if I'm adopted and don't know my biological family history?
Adopted patients can still be assessed for risk based on personal factors (breast density, hormonal history, biopsy history). Genetic testing is sometimes offered without family history — particularly if the patient has had an early-onset cancer or specific concerning features. The family-history clinic can advise.
Does it matter which side of the family the cancer is on?
Yes — both sides count, but they are assessed separately. A father with three sisters with breast cancer is a strong family-history signal even though the patient's mother's side may be unaffected. Risk-assessment tools take both maternal and paternal patterns into account.
Will my insurance cover family-history assessment?
Yes — UK private medical insurers usually cover specialist family-history assessment and (where indicated) genetic testing. Pre-authorisation is straightforward. Once a high-risk gene mutation is confirmed, risk-reducing surgery is also covered by major insurers as part of cancer-prevention treatment. See [fees and insurance](/fees-insurance/).

A family history of breast cancer is a pattern of breast or ovarian cancer in close relatives that raises a person’s own lifetime risk above the general population baseline — and triggers structured assessment, surveillance, and (where appropriate) genetic testing or risk-reducing options.

Most breast cancer is not inherited — only around 5–10% of cases are due to a recognised inherited gene1. But family history matters: even where no specific gene is identified, certain family patterns raise lifetime risk meaningfully and change what surveillance is offered. Knowing the threshold for action — and what to do at that threshold — is what this page covers.

Orientation Why you might be reading about this

You may be wondering whether your family history is significant enough to warrant assessment, or you have already been told it is. Either way, the key questions are: what counts as significant family history? What are the next steps? And what changes if a high-risk pattern is identified?

Related terms: BRCA · Mammogram · Breast MRI · Mastectomy · Risk-reducing mastectomy

Threshold What counts as a significant family history

The pattern of breast or ovarian cancer in the family is what matters — not just whether anyone has had it, but who, at what ages, and on which side of the family. Features that raise a family history into the “significant” category include:

  • A first-degree relative (mother, sister, daughter) with breast cancer under age 40.
  • Multiple first-degree relatives with breast cancer at any age.
  • A relative with bilateral breast cancer (cancer in both breasts).
  • A male relative with breast cancer — uncommon, and a stronger signal of an inherited cause.
  • A relative with ovarian cancer at any age — particularly significant when combined with breast cancer in the family.
  • A relative with pancreatic cancer — sometimes part of a BRCA-related family pattern.
  • Ashkenazi Jewish ancestry — associated with higher background frequency of certain BRCA mutations.
  • A known genetic mutation in the family (BRCA1, BRCA2, PALB2, TP53, others).

A single relative diagnosed in their 70s or 80s usually does not constitute a significant family history. The pattern matters more than the count.

Risk modelling How risk is formally assessed

Where the family history might be significant, formal risk assessment uses validated tools. UK practice distinguishes:

  • Lifetime breast-cancer risk tools — Tyrer-Cuzick (IBIS) and BOADICEA produce 10-year and lifetime cancer risk estimates used to categorise average, moderate, and high risk.
  • Carrier-probability tools — the Manchester score (and BOADICEA’s genetic module) estimate BRCA1/BRCA2 carrier probability; at ≥10% carrier probability, NICE CG164 recommends offering genetic testing.

Lifetime risk categories are:

  • Average / population risk — under ~17% lifetime risk1. Routine NHS Breast Screening Programme (mammograms 50–70 every three years) applies.
  • Moderate risk — ~17–30% lifetime risk1. Additional surveillance — usually annual mammograms from age 40 — is offered.
  • High risk — over ~30% lifetime risk, or known high-risk gene mutation1. Annual breast MRI from age 30 for BRCA1/BRCA2 carriers (from age 20 for TP53/Li-Fraumeni carriers), often with annual mammography from age 40. Genetic testing usually offered if not already done. Risk-reducing surgery is one of the options.

The thresholds vary slightly between guidelines (NICE CG164 in the UK is the standard reference1) but the structure is consistent.

Family clinics What family-history clinics offer

Patients identified as having significant family history are usually referred to a family-history clinic — typically run by a breast clinician or specialist breast nurse within the breast service, with onward referral to clinical genetics where carrier-probability criteria are met. The first appointment usually involves:

  • A detailed family-history interview, ideally with confirmation of relatives’ diagnoses where possible.
  • A formal risk calculation.
  • A discussion of genetic testing — what it can and cannot tell you, who in the family is the right starting point for testing.
  • A surveillance plan — what imaging, at what frequency, starting at what age.
  • A discussion of chemoprevention (tamoxifen or aromatase inhibitors) for moderate-to-high-risk patients.
  • For high-risk patients, a discussion of risk-reducing surgery — usually deferred to a later, separate appointment to give time to consider.

Suitability When genetic testing makes sense

Genetic testing for BRCA and other genes is most useful when:

  • There is already a confirmed family mutation — testing the patient is then a true positive/negative answer.
  • The family pattern strongly suggests an inherited cause — for example, multiple early-onset cancers in close relatives.
  • An affected family member is available to test first — testing an affected relative is more informative than testing an unaffected one. If the affected relative has a mutation, testing other family members becomes definitive.

For patients without a known family mutation, testing an affected relative first is preferred where possible. Where no affected relative is available, testing the unaffected patient can still be done — but the results are harder to interpret.

For more on what BRCA testing involves, see BRCA.

What changes What changes with significant family history

Even without a confirmed gene mutation, identification of a significant family-history pattern usually changes:

  • Surveillance — more frequent imaging starting at a younger age.
  • Imaging type — MRI is added in high-risk patients because it is more sensitive in the dense breast tissue typical of younger women.
  • Threshold for biopsy — any new finding is investigated more readily.
  • Discussion of chemoprevention and risk-reducing options — these are part of routine discussions in family-history clinics.

For first-degree relatives of patients with confirmed BRCA mutations, cascade testing — testing of relatives at known risk — is the standard pathway, usually arranged by clinical genetics rather than by individual self-referral.

At consultation What to discuss at consultation

If you have a family history of breast or ovarian cancer:

  • The specific pattern — who, when, and at what ages.
  • Whether formal risk assessment has been done, and where to access one if not.
  • The right entry point — most family-history conversations start with clinical genetics or a family-history clinic, not with a surgeon. Surgical input becomes relevant if a high-risk result is identified and risk-reducing options are being considered.
  • For GPs, the referral criteria page outlines when family history meets the threshold for onward referral.

Resources Further reading

Sources & guidance

Every figure on this page is anchored to a published source. Tap a number in the text or below to jump to the reference.

  1. guidance National Institute for Health and Care Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history. NICE clinical guideline CG164. London: NICE. 2019 https://www.nice.org.uk/guidance/cg164 Cited for: Risk thresholds (population/moderate/high), surveillance schedules, genetic testing criteria, chemoprevention guidance.
  2. cohort Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017 ;317(23):2402-2416 doi:10.1001/jama.2017.7112 Cited for: Lifetime breast cancer risk in BRCA1 (~72%) and BRCA2 (~69%) carriers; ovarian cancer risk; contralateral risk.